Sociedad Americana de Hirudoterapia

A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report

Case report published in Hematology (2022)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Case reportEnsayos clínicosDesarrollo de fármacosLazaro-Garcia A et al. · Hematology, 2022

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction associated with thrombosis. Clinical scoring systems and the presence of anti-platelet factor 4 (anti-PF4)/heparin antibodies determine the diagnosis. CASE PRESENTATION: A 57-year-old man who was treated with acenocoumarol due to a chronic left ventricular thrombus was admitted to the hospital for severe SARS-CoV-2 pneumonia and pulmonary embolism. The patient was started on bemiparin and discharged. Left lower limb acute arterial ischemia and thrombocytopenia were diagnosed 18 days later. Computed tomography angiography revealed a large left ventricular thrombus and multiple arterial thrombi. Left femoral-popliteal thromboembolectomy was performed. Anti-PF4/heparin antibodies confirmed an HIT diagnosis. Fondaparinux (7.5 mg/24 h) was initiated, but cardiac surgery was necessary. Bivalirudin was used during surgery, with an initial load (1.25 mg/kg) and maintenance infusion (2.5 mg/kg/h). The cardiac thrombus was extracted, but the patient experienced a postsurgical myocardial infarction. Percutaneous cardiovascular intervention (PCI) required a bivalirudin load (0.75 mg/kg) and maintenance infusion (1.75 mg/kg/h). No coronary lesions were detected, and argatroban was started afterwards (0.5 µg/kg/min). When the platelet count exceeded 100 × 109/L, acenocoumarol was initiated. Thereupon, acetylsalicylic acid (100 mg/24 h) was added. No other complications have been reported to date. CONCLUSION: The clinical presentation of intraventricular and multiple arterial thrombi is remarkable. SARS-CoV-2 infection likely contributed to a hypercoagulable state. The management of patients with HIT undergoing cardiac surgery is challenging. If surgery cannot be delayed, then treatment with bivalirudin is recommended. Additionally, this drug is recommended for PCI. Bivalirudin is safe and well-tolerated in both procedures.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleVideo-Audio Media
Indexed MeSH termsAcenocoumarolAnticoagulantsArginineCOVID-19HeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPercutaneous Coronary InterventionPipecolic Acids

Resumen

Detailed case of post-COVID-19 HIT with intraventricular and multiple arterial thrombi treated successfully with bivalirudin during cardiac surgery and PCI, then argatroban bridge — illustrates the role of hirudin-class anticoagulation in COVID-era hypercoagulability.

Por qué esto importa para la hirudoterapia

Este caso clínico describe a un hombre de 57 años con un trombo ventricular izquierdo crónico que desarrolló trombocitopenia inducida por heparina durante una neumonía grave por COVID-19 y fue sometido a cirugía cardíaca e intervención percutánea con bivalirudina, seguido de argatrobán, con posterior transición a acenocumarol y ácido acetilsalicílico. Los autores concluyen que la bivalirudina está recomendada para pacientes con trombocitopenia inducida por heparina que requieran cirugía cardíaca o ICP y parece ser segura y bien tolerada. El resumen no menciona lepirudina, hirudina, terapia con sanguijuelas ni ningún agente derivado de sanguijuelas. Para ASH, la conexión con la hirudoterapia o el secretoma de la sanguijuela está ausente; este caso documenta un manejo anticoagulante alternativo sin ninguna participación terapéutica relacionada con sanguijuelas.

Citación

A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report.

Lazaro-Garcia A et al. · Hematology, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.